Targeting KRAS Mutations in Advanced NSCLC

FDA grants 2 breakthrough therapy designations to Temab-A, speeding development for hard-to-treat colorectal cancer and c-Met–expressing lung cancer.

Lyudmila Bazhenova, MD, explains why the updated taletrectinib label does not change her practice and reviews new WCLC subgroup data in ROS1+ NSCLC.

Firmonertinib did not improve PFS in the phase 3 FURVENT trial in patients with EGFR exon 20 insertion–mutant NSCLC.

Submission of a new drug application for zipalertinib plus chemotherapy has begun under the FDA's RTOR program, based on phase 3 REZILIENT3 data showing a 6-month PFS gain.